Requires Medicaid managed care, and Child Health Plus plans to adopt the procedural protections of the Preferred Drug Program, including "prescriber prevails", for all drugs.
This bill would require Medicaid managed care plans, managed long-term care plans, Child Health Plus plans, and certain other approved organizations to cover prescription drugs through a “qualified prescription drug system” that is modeled on New York’s Preferred Drug Program. Under that system, drugs would be categorized as preferred or non-preferred, with prior authorization generally required for non-preferred drugs and not required for preferred drugs, subject to specified exceptions. The bill also allows the commissioner to approve a managed care provider’s system if it meets statutory criteria, including 24/7 access to prior authorization support, clinical review standards, and protections for emergency situations.
The bill sets detailed rules for when prior authorization must be granted, including when a patient has failed a preferred drug, experienced side effects, is stabilized on a non-preferred drug, or has other clinical indications. It also provides that if a prior authorization request is not completed within 24 hours because of system failure, authorization is automatically granted, and in other 24-hour delay cases a 72-hour supply must be approved. Certain drug classes are exempt from prior authorization, including atypical antipsychotics, antidepressants, antiretrovirals for HIV/AIDS or hepatitis C, and anti-rejection drugs for transplants, with additional classes possible by commissioner approval. The bill repeals existing social services law provisions related to prescription drug payments in managed care and aligns public health law provisions for Child Health Plus and the state preferred drug program with the new framework.
The bill would significantly change how prescription drug costs and utilization controls are handled in Medicaid managed care and Child Health Plus by tying drug payment to a state-approved preferred/non-preferred drug system. It would amend the Social Services Law and Public Health Law, repeal certain existing managed care prescription drug payment provisions, and require plans to either operate under the new qualified system or have prescription drugs carved out and provided through the state preferred drug program. The measure also updates the definition of the state public health plan and adds parallel prior-authorization protections for the preferred drug program, affecting Medicaid recipients, Child Health Plus enrollees, managed care organizations, prescribers, pharmacists, and the Department of Health.
The bill’s structure suggests a generally consumer- and provider-protective approach to prior authorization, with strong emphasis on timely access, clinical judgment, emergency supplies, and exemptions for certain mental health, HIV/AIDS, hepatitis C, and transplant medications. At the same time, it preserves utilization management and cost control by allowing preferred drug lists and prior authorization for non-preferred drugs. No committee transcripts or votes were provided, so there is no recorded public debate or roll-call sentiment in the supplied materials.
The main policy tension is between cost containment for the Medicaid program and access to clinically appropriate medications for patients. Supporters of the bill would likely favor the “prescriber prevails” style protections, automatic approval after delays, and broad exemptions for sensitive drug classes, while opponents may object that the bill limits managed care plans’ ability to use prior authorization and formulary controls to manage spending. Another likely point of contention is the requirement that prescribers’ professional judgment can be final after consultation, which may be viewed as reducing plan oversight, though the bill also includes fraud-and-abuse monitoring provisions.